Gallium Ga 68 Psma-11 Dosage

Usual Adult Dose for Positron Emission Tomography Imaging

Usual dose: 111 MBq to 259 MBq (3 mCi to 7 mCi) as a bolus intravenous injection

Comments:

• Initiate imaging 50 to 100 minutes after administration.
• A diuretic expected to act within the uptake time period may be administered at the time of radiotracer injection.
• Patient should void immediately prior to imaging.
• Scan should begin caudally and proceed cranially.

Uses: Radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in patients with prostate cancer:

• With suspected metastasis who are candidates for initial definitive therapy.
• With suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.
• For selection of patients with metastatic prostate cancer, with indication of lutetium Lu 177 vipivotide tetraxetan PSMA-direct therapy.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 18 years.
This drug is not recommended for use in children.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• Handle with appropriate safety measures to minimize radiation exposure.
• Use waterproof gloves, effective radiation shielding, and other appropriate safety measures when preparing and handling Ga 68 PSMA-11 Injection.

Storage requirements:

• Store upright in original container in a lead shielded container at 25C (77F); excursions are permitted from 15C to 30C (59F to 86F).
• Receipt, transfer, handling, possession, or use of this product is subject to the radioactive material regulations and licensing requirements of the U.S. Nuclear Regulatory Commission, Agreement States, or Licensing States as appropriate.

Reconstitution/preparation techniques:

• The manufacturer product information should be consulted for additional preparation, administration, imaging, and radiation dosimetry information.

IV compatibility: 0.9% Sodium Chloride Injection, USP

General:

• Radiopharmaceuticals should be used by or under the control of physicians specifically trained and experienced in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency.

Patient advice:

• Instruct patients to drink sufficient water to ensure adequate hydration before their PET study and urge them to drink and urinate as often as possible during the first hours after administration of this drug to reduce radiation exposure.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer